Press

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

May 12 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has received Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder (“AUD”) at Israel’s IMCA…

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 11 • 5 min read

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights. First Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $246.1 million as…

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

May 11 • 5 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an update on recent progress across its business. “Our phase 3 pivotal trials in treatment-resistant depression are now underway and on track, with…

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

May 11 • 8 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates. “We continue to focus on our vision to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. This past quarter we made significant…

Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting

May 11 • 2 min read

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces that it will present data from the long-term study of psilocybin therapy in cancer patients with major depressive disorder (MDD). The data will be presented in a poster presentation at the American Society…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441